Empowered Patient Podcast

Daniel Teper is the CEO and Founder of Cytovia Therapeutics and talks about using natural killer, NK, cells as an alternative to T-cells in immuno-oncology. He shares insights about the development of induced pluripotent stem cells, IPSC-derived NK cells, iNK cells, used by themselves or using their Flex-NK cell Engagers or in combination to address the challenges cancer patients face.

Daniel elaborates, "That's also where the NK cells may have advantages over T-cells, in that it hasn't been reported that they cause CRS, GBHD, or other side effects that would require the patients to be kept in the hospital. Now, if we say the first iteration was derived from the patient's own blood, the second iteration is donor, the third generation, which we are one of a handful of companies to pursue and master, is the production of immune cells, including NK cells, from induced pluripotent stem cells."

"We see also that you can direct the cells in two ways. You can direct the cells by inserting what's called a CAR, or chimeric antigen receptor, that's like a GPS on the cell. But alternatively, we can redirect the NK cells to kill the tumor cells by combining them with antibodies, and particularly with what we call NK engager antibodies. So our brand of NK engager antibodies is called Flex-NK cell engager antibodies. And what they do is that they have one arm that binds and activates the NK cell, and another arm that binds into the tumor cell, and the NK cells are redirected to kill the tumor cells."

@Cytovia #CytoviaTX #Oncology #ImmunoOncology #Cancer #CancerTherapeutics #CellTherapeutics #NKCells #iNKCells #NaturalKillerCells

CytoviaTX.com

Listen to the podcast here

Daniel Teper is the CEO and Founder of Cytovia Therapeutics and talks about using natural killer, NK, cells as an alternative to T-cells in immuno-oncology. He shares insights about the development of induced pluripotent stem cells, IPSC-derived NK cells, iNK cells, used by themselves or using their Flex-NK cell Engagers or in combination to address the challenges cancer patients face.

Daniel elaborates, "That's also where the NK cells may have advantages over T-cells, in that it hasn't been reported that they cause CRS, GBHD, or other side effects that would require the patients to be kept in the hospital. Now, if we say the first iteration was derived from the patient's own blood, the second iteration is donor, the third generation, which we are one of a handful of companies to pursue and master, is the production of immune cells, including NK cells, from induced pluripotent stem cells."

"We see also that you can direct the cells in two ways. You can direct the cells by inserting what's called a CAR, or chimeric antigen receptor, that's like a GPS on the cell. But alternatively, we can redirect the NK cells to kill the tumor cells by combining them with antibodies, and particularly with what we call NK engager antibodies. So our brand of NK engager antibodies is called Flex-NK cell engager antibodies. And what they do is that they have one arm that binds and activates the NK cell, and another arm that binds into the tumor cell, and the NK cells are redirected to kill the tumor cells."

@Cytovia #CytoviaTX #Oncology #ImmunoOncology #Cancer #CancerTherapeutics #CellTherapeutics #NKCells #iNKCells #NaturalKillerCells

CytoviaTX.com

Download the transcript here

Dr. Phil Kantoff is the CEO and Co-Founder and Alex Brown is the COO of Convergent Therapeutics which is developing the next generation of targeted therapies to treat cancer. Drawing on insights from developments in radiopharmaceuticals, Convergent focuses on radioantibodies that are radioisotopes attached to antibodies directed to treat prostate cancer.

Phil explains, "Antibodies will recognize surface molecules on cancer cells and they can be linked to radioisotopes. We are focused on an isotope known as Actinium-225, which is an important radioisotope because it's different than isotopes that have been previously used, it's an alpha-emitting radiopharmaceutical. Alpha particles are much larger, they're much more powerful, and they travel a shorter distance. You can deliver a very powerful, very targeted therapy to cancer."

"We have clinical trials that are taking place right now that are showing remarkable activity using the combination of the directed antibody against prostate cancer cells, specifically prostate-specific membrane antigen coupled to this isotope, Actinium-225."

Alex continues, "Our radioantibodies, which is what we're talking about here, are novel enough that there are few if any, examples of marketed products out there. It's a field that's emerging, so aside from having the experience in antibody development and commercialization, some of this is new to our team as well as to others."

@ConvergentRx @DrPhilKantoff #ProstateCancer #Radiopharmaceuticals #PSMA #Radioantibody #RadioLingandTherapy #Oncology #Biotechnology

ConvergentRx.com

Listen to the podcast here

Dr. Phil Kantoff is the CEO and Co-Founder and Alex Brown is the COO of Convergent Therapeutics which is developing the next generation of targeted therapies to treat cancer. Drawing on insights from developments in radiopharmaceuticals, Convergent focuses on radioantibodies that are radioisotopes attached to antibodies directed to treat prostate cancer.

Phil explains, "Antibodies will recognize surface molecules on cancer cells and they can be linked to radioisotopes. We are focused on an isotope known as Actinium-225, which is an important radioisotope because it's different than isotopes that have been previously used, it's an alpha-emitting radiopharmaceutical. Alpha particles are much larger, they're much more powerful, and they travel a shorter distance. You can deliver a very powerful, very targeted therapy to cancer."

"We have clinical trials that are taking place right now that are showing remarkable activity using the combination of the directed antibody against prostate cancer cells, specifically prostate-specific membrane antigen coupled to this isotope, Actinium-225."

Alex continues, "Our radioantibodies, which is what we're talking about here, are novel enough that there are few if any, examples of marketed products out there. It's a field that's emerging, so aside from having the experience in antibody development and commercialization, some of this is new to our team as well as to others."

@ConvergentRx @DrPhilKantoff #ProstateCancer #Radiopharmaceuticals #PSMA #Radioantibody #RadioLingandTherapy #Oncology #Biotechnology

ConvergentRx.com

Download the transcript here

Dr. Eric Brouwer is the Chief Scientific Officer for SQI Diagnostics, which believes that lung health is human health. Their focus is on the lung and ranges from COVID PCR, antigen, and antibody tests, across the spectrum to assessing lung transplant donors. With demand going up for lung transplants and new protocols for COVID screening of donors, diagnostic tests help better identify good candidates for organ donors.

Eric elaborates, "We're a Canadian-based company, and we have the distribution rights in Canada for a technology that was developed by the US military. The product is called Biomeme, and it's a portable PCR analyzer. So it does very rapid thermocycling that will enable the results to be delivered in just over two hours."

"This is deployed in mines and remote locations, on TV and film crew sets, and so that technology exists. We're using it, and that really makes that testing cycle reduced, so we can get same-morning tests, same-day testing, versus sending it in to a central lab which has the travel time, which has the review time, which has the execution time, that's pushing four to eight, sometimes 24 hours, before those results can get back. So the technology is out there, and it's becoming more widely available."

#SQI #COVID #COVIDTesting #PCRTest #Lungs #LungTransplants #Antibodies #Inflammation #LungDiagnostics #TransplantDiagnostics #PrecisionMedicine

SQIDiagnostics.com

Listen to the podcast here

Dr. Eric Brouwer is the Chief Scientific Officer for SQI Diagnostics, which believes that lung health is human health. Their focus is on the lung and ranges from COVID PCR, antigen, and antibody tests, across the spectrum to assessing lung transplant donors. With demand going up for lung transplants and new protocols for COVID screening of donors, diagnostic tests help better identify good candidates for organ donors.

Eric elaborates, "We're a Canadian-based company, and we have the distribution rights in Canada for a technology that was developed by the US military. The product is called Biomeme, and it's a portable PCR analyzer. So it does very rapid thermocycling that will enable the results to be delivered in just over two hours."

"This is deployed in mines and remote locations, on TV and film crew sets, and so that technology exists. We're using it, and that really makes that testing cycle reduced, so we can get same-morning tests, same-day testing, versus sending it in to a central lab which has the travel time, which has the review time, which has the execution time, that's pushing four to eight, sometimes 24 hours, before those results can get back. So the technology is out there, and it's becoming more widely available."

#SQI #COVID #COVIDTesting #PCRTest #Lungs #LungTransplants #Antibodies #Inflammation #LungDiagnostics #TransplantDiagnostics #PrecisionMedicine

SQIDiagnostics.com

Download the transcript here

Dave Lareau is the CEO of Medicomp Systems, which has spent 44 years working with providers to understand better the kinds of information that is most relevant to a diagnosis and therapeutic approach. With 400,000 concepts and tens of millions of relevancy links and mappings to data, Medicomp is prepared to handle the flood of information expected with the standardization of person-centered care. Just finalized in January, TEFCA, the Trusted Exchange Framework, and Common Agreement is expected to provide an infrastructure for sharing information.

Dave explains, "So there's a new era starting in healthcare, which is the data belongs to the patient. It doesn't belong to the provider or the organization. And now there's a framework in place for sharing it, a trusted framework. It's right in the name, TEFCA. And I think it's going to open up new possibilities, new opportunities, new challenges. And for the first time, the patient will be able to participate in the viewing and managing of their own care. It will radically change the way that people interact with information all along the continuum of care."

@MedicompSys #TEFCA #ElectronicHealthRecords #EHR #DataExchange #Interoperability

Medicomp.com

Listen to the podcast here

Dave Lareau is the CEO of Medicomp Systems, which has spent 44 years working with providers to understand better the kinds of information that is most relevant to a diagnosis and therapeutic approach. With 400,000 concepts and tens of millions of relevancy links and mappings to data, Medicomp is prepared to handle the flood of information expected with the standardization of person-centered care. Just finalized in January, TEFCA, the Trusted Exchange Framework, and Common Agreement is expected to provide an infrastructure for sharing information.

Dave explains, "So there's a new era starting in healthcare, which is the data belongs to the patient. It doesn't belong to the provider or the organization. And now there's a framework in place for sharing it, a trusted framework. It's right in the name, TEFCA. And I think it's going to open up new possibilities, new opportunities, new challenges. And for the first time, the patient will be able to participate in the viewing and managing of their own care. It will radically change the way that people interact with information all along the continuum of care."

@MedicompSys #TEFCA #ElectronicHealthRecords #EHR #DataExchange #Interoperability

Medicomp.com

Download the transcript

Wei Escala is the founder and CEO of Eggschain, the first biotech on the Bitcoin blockchain. This blockchain-integrated approach brings order to the management of tracking patient and biospecimen information. Their goal is to bring the healthcare industry to Web3 through decentralization.

Wei explains, "We're the first blockchain-enabled and blockchain-integrated inventory management and chain-of-custody solution for tracking all biospecimens. When I say all biospecimens, I mean sperm, eggs, embryos, genome, stem cells, tissues, organs, DNA and RNA, and more. So, essentially, we are the bridge between biology and blockchain. And our goal is to bring the healthcare industry to Web3 through decentralization."

"Yes, a blockchain-integrated platform helps tackle the problem of centralized records. Let me talk about what might be some of the issues of centralized records. Centralized records can be lost or can become inaccessible in times of need. And we all have heard that centralized records can be corrupted and can also be hacked. So, a blockchain approach, through decentralization, brings an added layer of security or backup to the current system."

@Eggschain #Eggschain #Blockchain #DigitalHealth #HealthRecords #Web3

Eggschain.com

Listen to the podcast here

Wei Escala is the founder and CEO of Eggschain, the first biotech on the Bitcoin blockchain. This blockchain-integrated approach brings order to the management of tracking patient and biospecimen information. Their goal is to bring the healthcare industry to Web3 through decentralization.

Wei explains, "We're the first blockchain-enabled and blockchain-integrated inventory management and chain-of-custody solution for tracking all biospecimens. When I say all biospecimens, I mean sperm, eggs, embryos, genome, stem cells, tissues, organs, DNA and RNA, and more. So, essentially, we are the bridge between biology and blockchain. And our goal is to bring the healthcare industry to Web3 through decentralization."

"Yes, a blockchain-integrated platform helps tackle the problem of centralized records. Let me talk about what might be some of the issues of centralized records. Centralized records can be lost or can become inaccessible in times of need. And we all have heard that centralized records can be corrupted and can also be hacked. So, a blockchain approach, through decentralization, brings an added layer of security or backup to the current system."

@Eggschain #Eggschain #Blockchain #DigitalHealth #HealthRecords #Web3

Eggschain.com

Download the transcript here